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Abstract
Background: Mier1 encodes a novel transcriptional regulator and was originally isolated as a
fibroblast growth factor early response gene. Two major protein isoforms have been identified,
MIER1α and β, which differ in their C-terminal sequence. Previously, we demonstrated that both
isoforms recruit histone deacetylase 1 (HDAC1) to repress transcription. To further explore the
role of MIER1 in chromatin remodeling, we investigated the functional interaction of MIER1 with
the histone acetyltransferase (HAT), Creb-binding protein (CBP).
Findings: Using GST pull-down assays, we demonstrate that MIER1 interacts with CBP and that
this interaction involves the N-terminal half (amino acids 1–283) of MIER1, which includes the acidic
activation and ELM2 domains and the C-terminal half (amino acids 1094–2441) of CBP, which
includes the bromo-, HAT, C/H3 and glutamine-rich domains. Functional analysis, using HEK293
cells, shows that the CBP bound to MIER1 in vivo has no detectable HAT activity. Histone 4 peptide
binding assays demonstrate that this inhibition of HAT activity is not the result of interference with
histone binding.
Conclusion: Our data indicate that an additional mechanism by which MIER1 could repress
transcription involves the inhibition of histone acetyltransferase activity.
Background
MIER1 is a newly described transcriptional regulator that
functions in anterioposterior patterning in the Xenopus
embryo [1] and as an inhibitor of anchorage-independent
growth of breast carcinoma cells [2]. Two major protein
isoforms, MIER1α and β, have been identified [3] and
structurally, these two isoforms share a number of
domains with other transcriptional regulators, including
ELM2 [4], SANT [5] and acid activation domains. At the
molecular level, MIER1 can both activate and repress tran-
scription. The former involves the N-terminal acidic acti-
vation domain [6] while repression occurs by at least two
distinct mechanisms: displacement of transcription fac-
tors, like Sp1, from their cognate binding sites [7] and
recruitment of the chromatin remodeling enzyme,
HDAC1 through its ELM2 domain [8]. Recently, studies
have shown that the SANT domain also plays a crucial
role in chromatin remodeling; in particular, this domain
is required for efficient histone acetylation [9]. In this
report, we extended our investigation of MIER1 in chro-
matin remodeling by examining its ability to interact with
CBP and regulate its HAT activity.
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Methods
The GST fusion and myc-tagged hmi-er1β (GenBank:
NM_001077701) sequences were constructed using
pGEX-4T-1 and pCS3+MT plasmids, respectively and their
production has been described elsewhere [7,8]. The full-
length mouse CBP (GenBank: NM_001025432) in pRc/
RSV was a kind gift from Dr. Roland Kwok (University of
Michigan). CBP 1–1096 and CBP1094–2441 were constructed
by PCR amplification of the full-length sequence using 5'-
ggggatccatggccgagaacttgctggacg-3' (forward) with 5'-
cgggatccctacataagtgcctggcgtagctcctcg-3' (reverse) and 5'-
ggggatccgcacttatgccaactctagaag-3' (forward) with 5'-ccg-
gatccctacaaaccctccacaaactttt-3' (reverse), respectively. The
PCR products were digested with BamH1 and inserted
into the BamH1 site of the pCMV-Tag2B vector (Strata-
gene). Anti-myc hybridoma supernatant was prepared
from 9E10 cells (ATCC) [10] grown in hybridoma serum-
free media (Invitrogen, Inc.) supplemented with 1% Opti-
Mab monoclonal antibody production enhancer (Invitro-
gen, Inc.). GST pull-down assays were performed as in [7],
using 0.35 μg of GST or equimolar amounts of GST fusion
proteins and 100,000 cpm of 35S-labeled in vitro transla-
tion products. Transient transfections were performed as
in [8]. HAT assays were performed as in [11]; briefly, cell
lysates were subjected to immunoprecipitation with the
indicated antibody and the washed beads incubated with
100 nCi [14C]acetyl-CoA (51 mCi/mmol, Amersham), 30
μM H4 biotinylated peptide (Upstate Biotechnology Inc.)
and 300 nM trichostatin A (Sigma) in HAT buffer [11] for
45 min at 30°C. The supernatants were collected and
incubated with streptavidin-agarose (Pierce) at 4°C for 20
min; the 14C incorporated into the bound H4 peptide was
determined by liquid scintillation counting.
Results and discussion
The N-terminal half of MIER1 interacts with the C-
terminal half of CBP
We investigated a possible interaction between MIER1β
and CBP, using pull-down assays. 35S-labelled flag-tagged
CBP constructs (Figure 1A), synthesized in vitro, were
incubated with a full-length GST-MIER1β fusion protein.
CBP was detected in the pull-down with GST-MIER1β, but
not with GST alone (Figure 1B). Furthermore, only the C-
terminal half of CBP, consisting of the bromo-, HAT, C/
H3 and glutamine-rich domains, interacted with MIER1β
(Figure 1B). To determine which domain(s) of MIER1β
were required for binding, two deletion mutants were
constructed: one consisting of the N-terminal half, which
includes the acidic activation and ELM2 domains, and a
second consisting of the C-terminal half, which includes
the SANT domain and beta-specific C-terminus (Figure
1C). As can be seen in Figure 1D, only the N-terminal half
(amino acids 1–283) of MIER1 was able to bind CBP.
Since this construct contains sequence that is common to
both MIER1α and β, one would expect that MIER1α
Figure 1BMC Research Notes 2008, 1:68 http://www.biomedcentral.com/1756-0500/1/68
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would also interact with CBP. Interestingly, this region
does not include the SANT domain, a domain known to
play an important role in the histone acetyltransferase
(HAT) activity of several chromatin remodelling com-
plexes [12].
Binding of MIER1 results in inhibition of CBP HAT activity
To explore the functional consequence of MIER1-CBP
interactions, we performed HAT assays on extracts from
HEK293 cells co-transfected with flag-tagged CBP1094–2441
(flag-CBP) and myc-tagged full-length MIER1β (myc-
mier1). Parallel samples were subjected to immunopre-
cipitation (IP) with the relevant antibody and the pellets
assayed for interaction with MIER1β by Western blot or
for HAT activity using 14C-labelled acetyl-CoA and a bioti-
nylated histone 4 (H4) peptide. Acetylated H4 was recov-
ered using streptavidin-agarose and the level of
incorporation measured by liquid scintillation counting.
Western blot analysis was used to confirm the expression
of MIER1β (Fig. 2A, panel i) and CBP (Figure 2A, panel ii)
in transfected cells.
As expected, no HAT activity was detectable in immuno-
precipitates from cells transfected with empty vector or
mier1β (Figure 2B, lanes 2–3), however high levels of HAT
activity were measured in those from cells expressing CBP
alone (Fig. 2B, lane 4). When CBP was co-immunoprecip-
itated with MIER1β on the other hand, no detectable HAT
activity was recovered in the pellet (Fig. 2B, lane 5). The
presence of CBP in the co-IP was verified in a parallel sam-
ple subjected to Western blot analysis with anti-flag (Fig.
2A, panel iii, lane 3). These data show that when associ-
ated with MIER1β, CBP has no detectable HAT activity.
MIER1 does not interfere with histone binding to CBP
The inhibitory effect of MIER1β on CBP HAT activity
could result from interference with histone binding or
from a direct effect on the HAT catalytic domain. To test
whether interaction with MIER1β interferes with CBP's
ability to bind to histone, we measured the ability of CBP
to interact with H4 peptide in the presence or absence of
MIER1 interacts with CBP Figure 1
MIER1 interacts with CBP. (A) Schematic illustrating the 
CBP protein sequence and its domains: NR = nuclear recep-
tor interaction domain, C/H1 and C/H3 = cysteine/histidine 
rich regions, KIX = kinase-induced interacting domain, Br = 
bromodomain, HAT = histone acetyltransferase domain, 
QRD = glutamine-rich domain. (B) GST pull-down assays 
using CBP deletion mutants. In vitro translated, 35S-labelled, 
full-length CBP (panel i), CBP1–1096 (panel ii) or CBP1094–2441 
(panel iii) were incubated with 0.35 μg GST (lane 2) or an 
equimolar amount of GST-MIER1β fusion protein (lane 3). 
One twentieth of the labelled protein input is shown in lane 
1. (C) Schematic illustrating the MIER1β sequence and its 
domains: acidic activation, ELM2 and SANT domains as well 
as the β-specific C-terminus. (D) GST-pull-down assays using 
MIER1β deletion mutants. In vitro translated, 35S-labelled 
CBP1094–2441 was incubated with 0.35 μg of GST alone (lane 
2) or equimolar amounts of GST fusions of full-length 
MIER1β (lane 1), the N-terminal half (lane 3) or C-terminal 
half (lane 4) of MIER1β. One twentieth of the labelled protein 
input is shown in lane 5. (E) Coomassie blue-stained gel 
showing the GST fusion proteins used in panel D.
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MIER1. In vitro translated  35S-labelled CBP1094–2441 was
incubated with biotinylated H4 peptide in the presence of
a 400-fold molar excess of GST alone or GST-MIER11–283
fusion protein; the complex was precipitated using
streptavidin-agarose and analyzed by autoradiography. As
can be seen in Figure 3, the level of CBP associated with
H4 peptide in the presence of GST-MIER1 (lane 2) was the
same as that in the presence of GST alone (lane 3), dem-
onstrating that the interaction of CBP with H4 peptide
was not affected by MIER1.
Together, our data show that MIER1 physically interacts
with CBP and inhibits its HAT activity; this inhibition is
not the result of interference with histone binding but is
possibly due to a direct effect on the HAT catalytic
domain.
Abbreviations
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